Stockreport

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding [Seeking Alpha]

Ovid Therapeutics Inc.  (OVID) 
Last ovid therapeutics inc. earnings: 3/11 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.ovidrx.com
PDF Recent Phase 1 data show OV329 lacks the eye toxicity seen with vigabatrin, supporting its differentiated safety profile. Management secured $60M PIPE financing, exte [Read more]